Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity 

Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet

Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population 

Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit 

The optimal chemotherapy regimen in this setting is not well-defined 

Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies

In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib

Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients 

Results of a small phase II trial may open up a new option for some patients with leukoplakia, but toxicity of immunotherapy is high and questions remain about its utility in clinical practice